Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118257672 | 11825767 | 2 | F | 199909 | 20160829 | 20151211 | 20160901 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-10598563 | BRISTOL MYERS SQUIBB | 0.00 | M | Y | 2.83000 | KG | 20160901 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118257672 | 11825767 | 1 | PS | ZERIT | STAVUDINE | 1 | Oral | UNK | U | 20412 | |||||||||
| 118257672 | 11825767 | 2 | SS | VIDEX | DIDANOSINE | 1 | Oral | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 3 | SS | ZERIT | STAVUDINE | 1 | Transplacental | UNK | U | 20412 | |||||||||
| 118257672 | 11825767 | 4 | SS | VIDEX | DIDANOSINE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 5 | SS | VIRACEPT | NELFINAVIR MESYLATE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 6 | SS | VIRAMUNE | NEVIRAPINE | 1 | Oral | 1 DF, UNK | U | 0 | 1 | DF | SYRUP | ||||||
| 118257672 | 11825767 | 7 | SS | VIRAMUNE | NEVIRAPINE | 1 | Transplacental | 1 DF, UNK | U | 0 | 1 | DF | SYRUP | ||||||
| 118257672 | 11825767 | 8 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 9 | C | LOXEN | NICARDIPINE HYDROCHLORIDE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 10 | C | SALBUTAMOL | ALBUTEROL | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118257672 | 11825767 | 11 | C | CELESTENE | BETAMETHASONE | 1 | Transplacental | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118257672 | 11825767 | 1 | HIV infection |
| 118257672 | 11825767 | 2 | HIV infection |
| 118257672 | 11825767 | 3 | HIV infection |
| 118257672 | 11825767 | 4 | HIV infection |
| 118257672 | 11825767 | 5 | HIV infection |
| 118257672 | 11825767 | 6 | Antiretroviral therapy |
| 118257672 | 11825767 | 7 | HIV infection |
| 118257672 | 11825767 | 8 | Product used for unknown indication |
| 118257672 | 11825767 | 9 | Product used for unknown indication |
| 118257672 | 11825767 | 10 | Product used for unknown indication |
| 118257672 | 11825767 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118257672 | 11825767 | OT |
| 118257672 | 11825767 | HO |
| 118257672 | 11825767 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118257672 | 11825767 | Anaemia macrocytic | |
| 118257672 | 11825767 | Blood creatine phosphokinase increased | |
| 118257672 | 11825767 | Blood lactic acid increased | |
| 118257672 | 11825767 | Foetal exposure during pregnancy | |
| 118257672 | 11825767 | Hypertriglyceridaemia | |
| 118257672 | 11825767 | Neutropenia | |
| 118257672 | 11825767 | Skull malformation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118257672 | 11825767 | 5 | 19990913 | 0 | ||
| 118257672 | 11825767 | 6 | 19990913 | 19990913 | 0 | |
| 118257672 | 11825767 | 7 | 19990915 | 0 |